Hormones and Surgery: The Risk Is Specific, Not General
If you take any form of hormonal therapy — birth control pills, patches, rings, IUDs, hormone replacement therapy, or gender-affirming hormones — your BBL surgeon needs to know. Not because hormones are universally dangerous before surgery, but because specific hormones carry specific risks that affect surgical planning.
The primary concern is venous thromboembolism (VTE) — blood clots in the deep veins (DVT) that can travel to the lungs (pulmonary embolism). Estrogen-containing medications increase this risk significantly. Other hormonal preparations have lower or no clotting risk. The distinction matters for your safety, and a blanket instruction to "stop all hormones" is overly simplistic.
Estrogen-Containing Birth Control
Combined oral contraceptives (the pill), patches, and vaginal rings all contain synthetic estrogen (ethinyl estradiol) combined with a progestin. These preparations increase VTE risk by three to four times over baseline — a well-documented effect that has been known for decades.
Most plastic surgeons recommend stopping estrogen-containing contraceptives two to four weeks before surgery and not restarting until two weeks after, once you are fully mobile. During this window, use a non-hormonal contraceptive method (condoms, copper IUD, or abstinence).
If you cannot stop your birth control for medical reasons (severe endometriosis, PCOS management), discuss the risk-benefit calculus with both your surgeon and your gynecologist. Enhanced VTE prophylaxis (compression, early ambulation, possibly enoxaparin) may be appropriate.
Progestin-Only Methods
Progestin-only pills (mini-pill), hormonal IUDs (Mirena, Kyleena), and the Depo-Provera injection do not contain estrogen and do not carry the same VTE risk. Most surgeons do not require stopping progestin-only methods before surgery. The hormonal IUD, in particular, does not need to be removed.
If you are unsure whether your contraceptive is estrogen-containing or progestin-only, check the package insert or ask your prescribing provider. The distinction is critical and should not be guessed at.
Menopausal Hormone Replacement Therapy (HRT)
Oral estrogen-based HRT carries a VTE risk similar to combined oral contraceptives. Transdermal estrogen (patches, gels) carries a lower VTE risk than oral estrogen — published data suggests that transdermal estrogen does not significantly increase clotting risk compared to no HRT.
If you are on oral HRT, your surgeon will likely recommend switching to transdermal delivery or pausing HRT for two to four weeks around surgery. If you are already on transdermal HRT, many surgeons allow continuation with enhanced monitoring. Discuss with both your surgeon and your menopause care provider.
Gender-Affirming Hormone Therapy
Estrogen-based therapy (transfeminine patients): Carries VTE risk. The management approach is individualized — some surgeons recommend dose reduction for two to four weeks before and after surgery; others proceed without modification if the patient's overall risk profile is low and enhanced VTE prophylaxis is used. Complete cessation is generally avoided because of the psychological impact of hormone interruption.
Testosterone-based therapy (transmasculine patients): Does not carry estrogen-related VTE risk. Most surgeons do not require stopping testosterone before BBL or body contouring surgery. Testosterone may affect hemoglobin levels (tending to increase them), which your pre-operative labs will capture.
Hormonal Therapy and BBL: What to Stop, What to Keep
| Therapy | Before BBL | Notes |
|---|---|---|
| Combined pill / patch / ring (estrogen + progestin) | Stop 2–4 weeks before surgery | Resume 2 weeks post-op when fully mobile |
| Progestin-only pill / Depo-Provera | Continue | No estrogen = no added VTE risk |
| Hormonal IUD (Mirena, Kyleena) | Continue (do not remove) | Progestin-only; no VTE risk |
| Oral HRT (estrogen) | Stop or switch to transdermal 2–4 weeks before | Discuss with menopause provider |
| Transdermal HRT (patch/gel) | Usually continue with monitoring | Lower VTE risk than oral |
| Gender-affirming estrogen | Individualized (reduce or continue with prophylaxis) | Do not stop without coordinating with prescribing physician |
| Testosterone | Continue | No estrogen-related VTE risk; check hemoglobin pre-op |
Frequently Asked Questions
Do I have to stop birth control before BBL?
If your birth control contains estrogen (combined pill, patch, or ring), most surgeons recommend stopping 2–4 weeks before surgery. Progestin-only methods (mini-pill, hormonal IUD, Depo-Provera) do not need to be stopped.
Can I get a BBL while on HRT for menopause?
Yes, with appropriate management. Oral estrogen HRT should be paused or switched to transdermal delivery around surgery. Transdermal HRT is generally continued. Discuss with your surgeon and menopause provider.
Will stopping birth control before BBL cause side effects?
Stopping estrogen-containing contraceptives may cause breakthrough bleeding, mood changes, or acne. These effects are temporary. Use a non-hormonal contraceptive method during the gap.